This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2021-22. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

Childhood Vaccination Coverage Statistics- England 2017-18 [NS] The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood vaccination coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs). Information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through PHE's ImmForm system.

The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood immunisation coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs) and Primary Care Trusts (PCTs). Information on persons aged 65 and over immunised against seasonal flu is collected from GPs through PHE’s ImmForm system.

Update 23 December 2019. NHS Digital have been made aware of an error in the csv version of Table 5b which previously contained data relating to Table 5c, the data contained within the file was labelled as 5c. This incorrect csv file has now been replaced. Please note that this error did not affect the Excel data file which contained the correct data. The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood immunisation coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs). Information on children aged 2, 3 and 4 immunised against seasonal flu are collected from GPs through PHE's ImmForm system. The 2016-17 report is accompanied by a new interactive data dashboard which has been developed in collaboration with Public Health England.. To access the dashboard and its functionality, one of the following internet browsers is required • Microsoft Edge • Internet Explorer 11 or later • Chrome desktop latest version • Safari Mac latest version • Firefox desktop latest version This tool is in Microsoft PowerBI which does not fully support all accessibility needs. If you need further assistance, please contact us for help.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

This statistic displays the share of children who received a first dose and a second dose of Measles, Mumps and Rubella (MMR) immunization in England, from 2003/04 to 2023/24. In the year 2023/24, 83.9 percent of children had received their MMR immunization by their fifth birthday.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Centre for Infections (CfI) for information on childhood immunisation uptake at ages 1, 2 and 5 collected through the Cover of Vaccination Evaluated Rapidly (COVER).

Long-term trends for MMR immunisations in London and England are available, back to 1988/89. It is not possible to easily display the long term trends for all regions since the definitions and boundaries of the other English regions has changed a number of times during this period - though data for London has always remained available.

Related links: http://www.hscic.gov.uk/Article/1685

This dataset was collected from men who have sex with men (MSM), who were recruited online. It refers to a study exploring 1) uptake of the HPV vaccine among MSM and 2) determinants of uptake. Full details of the method will be available in a published paper - link to follow.

The Office for Health Improvement and Disparities (OHID) has published the Public Health Outcomes Framework (PHOF) quarterly data update for May 2022.

The data is presented in an interactive tool that allows users to view it in a user-friendly format. The data tool also provides links to further supporting information, to aid understanding of public health in a local population.

18 indicators have been updated in this release:

• healthy life expectancy and disability-free life expectancy at birth and at 65
• 7 indicators from the health improvement domain including conception rates in teenagers, percentage of looked after children whose emotional wellbeing is a cause for concern, and percentage of physically active adults
• 4 indicators from the health protection domain including the fraction of mortality attributable to particulate air pollution (new method), population vaccination coverage for human papillomavirus (HPV) vaccination coverage for two doses (females 13 to 14 years old) and population vaccination coverage - Meningococcal ACWY conjugate vaccine (MenACWY) (14 to 15 years)
• 5 indicators from the healthcare and premature mortality domain including emergency readmissions within 30 days of discharge from hospital and preventable sight loss

See links to indicators updated document for full details of what’s in this update.

View previous Public Health Outcomes Framework data tool updates.

Percentage of children immunised (for three immunisations, diphtheria, tetanus and polio) by their fifth birthday

Source: Health and Social Care Information Centre (HSCIC)

Publisher: Department of Health

Geographies: Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA)

Geographic coverage: England

Time coverage: 2004/05

Type of data: Administrative data

Pairwise comparisons for the Irish (N = 1,030) and UK (N = 2,020) samples.

This dataset contains data from WHO's data portal covering the following categories:

Adolescent, Ageing, Air pollution, Assistive technology, Child, Child mortality, Cross-cutting, Dementia diagnosis, treatment and care, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, Global Patient Safety Observatory, Global strategy, HIV, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, Malaria, Maternal and newborn, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence prevention, Water, sanitation and hygiene (WASH), World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. Read More

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck’s Gardasil, with GlaxoSmithKline’s (GSK’s) HPV vaccine Cervarix providing the only competition. The introduction of Merck’s nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. In 2006 Gardasil (marketed as Silgard in Germany) became the first vaccine approved for prophylactic protection against HPV infection. Gardasil was primarily developed and marketed by Merck, under license from Australian biotechnology company CSL, which markets the vaccine in Australia and New Zealand. Gardasil is a quadrivalent vaccine containing recombinant virus-like particles (VLPs) of the L1 capsid protein from the HPV strains 6, 11, 16 and 18, combined with an aluminum adjuvant (amorphous aluminum hydroxyphosphate sulfatez Read More